Time has been keeping readers apprised of news since 1923, and scholars in every discipline have been both reported about and reading the venerable newsweekly.
On March 1, 2004 – thanks to Time, the relationship between consumers and their inner selves changed for good: the first widespread, in-depth reporting associating unfelt inflammation and its stirring up of myriad diseases was presented to all and sundry:
Since then, both pharmaceuticals and nutraceuticals pioneers have been working on finding substances that can reduce the inflammatory signaling system, which decreases overall inflammation within the body.
This article has indeed inspired many missions: and one such pioneer whose previous work was already on track was Juan L. Hancke, PhD, DVM, the world’s foremost authority on the pharmacophysiology of Andrographis paniculata. Dr. Hancke is globally distinguished by having 20 patents and 80 published scientific papers, (which include book chapters, articles, reviews, and abstracts).
Dr. Hancke helped create the unique, patented A. paniculata extract, ParActin®. tstandardized to andrographolide, 14- deoxyandrographolide, and neoandrographolide. (US Patent No: 8,084,495 B2), with over 30 published andrographolide articles.
Preliminary research has shown ParActin® to promote healthy inflammatory response by naturally invigorating the PPAR gamma response, inhibiting NF-kappaB, the key regulator of our inflammatory response system, thereby naturally reducing pro-inflammatory cytokines and proteins associated with pain and redness from everyday activities.
ParActin® is the result of 40 arduous years of research and development. It boasts more than 30 studies, including in vitro, in vivo animal models and human clinical trials. ParActin® has been researched and developed to support healthy NF-kB levels and activity, which, in turn, helps support a healthy and appropriate inflammatory response. As a result, ParActin® is suitable for dietary supplements that support the following condition-specific areas:
- Joint Health
- Healthy Bones
- Healthy Cartilage
- Sports Recovery/Muscle Function
- Healthy Inflammatory Response
- Overall Immune Function
New advancements and studies on ParActin®
In 2019, we published a double-blind, randomized, placebo-controlled study in Phytotherapy Research. 103 participants were given a placebo, 300mg or 600mg of ParActin® for 12 weeks. ParActin® significantly reduced WOMAC Pain & Stiffness score, reduced fatigue, and improved the Quality of Life score.
In 2020, we published a double-blind, randomized, placebo-controlled trial in BMC Neurology. The study included 44 participants who were given either 140mg of ParActin® or placebo for 24 months. ParActin® significantly promoted stable activity as well as physical and mental energy. This clinical supports our previous animal research that showed ParActin® reduces neuro-inflammation and stimulates neurogenesis.
Inflammation is now recognized by consumers to be a condition they can control through healthy habits including and specifically highlighting the consumption of dietary supplements, such as botanicals. And ParActin® A. paniculata is at the pinnacle of this research.